Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.60 |
| ▸ | TUBB | P07437 | 4/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.60 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.60 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.60 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.60 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.60 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537250 | 0.83 | CA2 (0.52) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL542723 | 0.81 | MAOB (0.47) | ABCB1 | |
| SCHEMBL8558338 | 0.80 | DHFR (0.40) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL9863964 | 0.77 | TUBB4A (0.66) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL873803 | 0.77 | TUBB1 (0.40) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7252472 | 0.75 | TUBB4A (0.54) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL864988 | 0.75 | APP (0.65) | — | |
| SCHEMBL6741410 | 0.75 | PARP10 (0.54) | — | |
| SCHEMBL5535297 | 0.75 | CA12 (0.38) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4600665 | 0.74 | TUBB1 (0.61) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | claimed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | claimed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | claimed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TUBB1 726/4885TUBB4A 1423/4885TUBB 1089/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TUBB1 777/4885TUBB4A 1410/4885TUBB 1169/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TUBB1 593/4885TUBB4A 1168/4885TUBB 919/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TUBB1 593/4885TUBB4A 1168/4885TUBB 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.